Roche Pharma Research and Early Development (pRED), Therapeutic Modalities - Large Molecule Research, Roche Innovation Center Munich, Nonnenwald 2, D-82377 Penzberg, Germany.
Biochemistry III; Biochemistry Centre Regensburg (BCR), University of Regensburg, Regensburg, Germany.
Nucleic Acids Res. 2019 Jun 4;47(10):e55. doi: 10.1093/nar/gkz137.
We report a novel system for efficient and specific targeted delivery of large nucleic acids to and into cells. Plasmid DNA and core histones were assembled to chromatin by salt gradient dialysis and subsequently connected to bispecific antibody derivatives (bsAbs) via a nucleic acid binding peptide bridge. The resulting reconstituted vehicles termed 'plasmid-chromatin' deliver packaged nucleic acids to and into cells expressing antigens that are recognized by the bsAb, enabling intracellular functionality without detectable cytotoxicity. High efficiency of intracellular nucleic acid delivery is revealed by intracellular expression of plasmid encoded genes in most (∼90%) target cells to which the vehicles were applied under normal growth/medium conditions in nanomolar concentrations. Specific targeting, uptake and transgene expression depends on antibody-mediated cell surface binding: plasmid chromatin of identical composition but with non-targeting bsAbs or without bsAbs is ineffective. Examples that demonstrate applicability, specificity and efficacy of antibody-targeted plasmid chromatin include reporter gene constructs as well as plasmids that enable CRISPR/Cas9 mediated genome editing of target cells.
我们报告了一种新型系统,可有效地将大型核酸特异性靶向递送至细胞内。通过盐梯度透析将质粒 DNA 和核心组蛋白组装成染色质,随后通过核酸结合肽桥将其连接至双特异性抗体衍生物(bsAb)。由此产生的重组载体称为“质粒-染色质”,可将包装的核酸递送至表达 bsAb 识别的抗原的细胞内,使细胞内功能得以实现,而不会产生可检测的细胞毒性。在正常生长/培养基条件下,以纳摩尔浓度将载体应用于大多数(约 90%)靶细胞,通过细胞内表达质粒编码的基因可揭示出细胞内核酸递送的高效率。特异性靶向、摄取和转基因表达取决于抗体介导的细胞表面结合:具有相同组成但没有靶向 bsAb 或没有 bsAb 的质粒染色质是无效的。证明抗体靶向质粒染色质适用性、特异性和功效的实例包括报告基因构建体以及可实现靶细胞 CRISPR/Cas9 介导的基因组编辑的质粒。